Chris Ryan

Adjuvant atezolizumab improved DFS and OS after a positive Signatera MRD test in muscle-invasive bladder cancer.

Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.

Real-world data supported the clinical effectiveness of first-line palbociclib plus endocrine therapy in HR-positive, HER2-negative breast cancer.

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

The FDA granted regenerative medicine advanced therapy designation to GLPG5101 for relapsed/refractory mantle cell lymphoma.

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

The FDA provided feedback on next steps of development for eftilagimod alfa in PD-L1–negative recurrent/metastatic head and neck squamous cell carcinoma.

Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

The combination of talazoparib and tazemetostat was safe and led to PSA reductions in certain patients with metastatic castration-resistant prostate cancer.

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.